Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eligard 6-month biomarker study in metastatic prostate cancer
NL-OMON40179Phase 4Active, not recruiting
- Sponsor
- Astellas Pharma
- Start
- May 2014
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of leuprolide in Metastatic Prostate Cancer (mPC), sponsored by Astellas Pharma. Primary endpoints: Change from baseline in serum testosterone, Change from baseline in serum PSA and 5 more. Started May 2014; status: active, not recruiting.
02
Drugs
leuprolide
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NL-OMON40179.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40179.